A Safer Flu Spray? China's New Vaccine Aims to Protect the Vulnerable

HANGZHOU, China – February 09, 2026 – In a significant step for both vaccine technology and China's burgeoning biotech sector, Zhejiang Difference Biological Technology Co., Ltd. (DIFF Biotech) has received clinical trial approval for an innovative nasal spray influenza vaccine. The vaccine, named DIFF-flu, leverages a novel gene-modification strategy that could overcome critical safety limitations of existing nasal sprays, potentially extending needle-free flu protection to millions of older adults and immunocompromised individuals for the first time.

The approval from China's National Medical Products Administration (NMPA) designates DIFF-flu as a Class 1.2 innovative vaccine, marking it as the first domestically developed nasal spray flu vaccine in the country to advance to human trials. This milestone not only highlights the company's scientific progress but also signals a new chapter in the global effort to improve influenza prevention.

"DIFF-flu's clinical approval marks a major milestone for DIFF Biotech and a meaningful achievement for independent innovation in respiratory infectious disease prevention," said Dr. Jiasheng Song, Chief Executive Officer of DIFF Biotech, in a statement. He emphasized the design goal of achieving an "optimal balance between immunogenicity and safety," which holds the potential to expand access to more effective flu prevention, particularly for vulnerable populations.

A New Blueprint for Vaccine Safety

At the heart of DIFF-flu's innovation is its unique method of weakening, or attenuating, the influenza virus. Current nasal spray vaccines on the market, such as AstraZeneca's FluMist, use a "cold-adapted" attenuation strategy. These vaccine viruses are designed to replicate effectively in the cooler temperatures of the nasal passages but poorly in the warmer environment of the lungs. While effective, this approach still involves viral replication in the nose, which can lead to mild viral shedding. This shedding risk is why such vaccines are generally not recommended for individuals with weakened immune systems or for adults over the age of 50.

DIFF Biotech has taken a different path. DIFF-flu is engineered using an M2 gene-modification strategy, which creates a replication-restricted vaccine strain. This proprietary technology essentially places a "safety harness" on the virus, severely limiting its ability to replicate uncontrollably while still training the immune system to recognize and fight off a real infection.

According to preclinical data released by the company, this approach results in negligible viral shedding and significantly reduced viral loads in respiratory tissues. This differentiated safety profile is the key to its potential to be used by older adults and other at-risk groups who are most susceptible to severe complications from influenza but are currently excluded from existing nasal spray options. Furthermore, the company reported that preclinical studies showed the vaccine conferred 100% protection against historical flu strains from over 50 years ago, while also generating a strong immune response against contemporary variants.

China's Biotech Innovation Comes of Age

The approval of DIFF-flu for clinical trials is more than just a corporate achievement; it is a testament to China's rapidly evolving role in global pharmaceutical innovation. The NMPA's 'Class 1.2' designation is reserved for new vaccines not yet marketed anywhere in the world, and it often benefits from expedited review pathways designed to foster domestic R&D. For years, China has been reforming its regulatory landscape to align with international standards and accelerate patient access to novel therapies, a strategy that is now bearing fruit.

DIFF Biotech, recognized as a 'Quasi-Unicorn' enterprise, exemplifies this trend. The company has built an extensive portfolio of over 70 patents around its proprietary Viraltech Architect Platform, which underpins its work in mucosal vaccines, antivirals, and even gene therapy. By developing a highly differentiated product from the ground up, the company is moving beyond imitation and contributing a potentially significant innovation to global health.

This domestic breakthrough is particularly relevant given China's public health landscape. With an influenza vaccination rate of approximately 3.8%, far below the nearly 50% coverage in the United States, there is a massive unmet need. A convenient, domestically produced, and potentially safer nasal spray could be a critical tool in boosting these numbers and protecting its large aging population.

Reshaping the Global Fight Against Influenza

The need for better influenza vaccines is a pressing global issue. The World Health Organization estimates that seasonal flu infects up to a billion people annually, causing up to 650,000 respiratory deaths. Older adults bear the brunt of this burden, facing higher risks of severe complications like pneumonia, myocarditis, and acute cardiorespiratory failure.

Nasal spray vaccines are seen as a vital tool in this fight because they induce mucosal immunity directly at the point of viral entry—the nose and throat—creating a first line of defense that injectable vaccines cannot. This can be more effective at not only preventing disease but also curbing transmission.

"Any technology that can safely expand the pool of people eligible for a more effective vaccine platform is a welcome development," commented one independent virologist not associated with the company. "The challenge with influenza is twofold: vaccine efficacy and vaccine uptake. A needle-free option that is safe for the elderly addresses both sides of that equation."

A Market Primed for Convenience

The development of DIFF-flu arrives at a pivotal moment for vaccine distribution. In a landmark decision in September 2024, the U.S. FDA authorized at-home, self-administration for a nasal spray influenza vaccine. This move shattered the traditional model of requiring a healthcare provider for every vaccination, paving the way for direct-to-consumer distribution through online pharmacies.

This regulatory precedent significantly boosts the commercial and public health potential for any new, user-friendly vaccine. For a product like DIFF-flu, which aims to be safer for a broader population, the prospect of future at-home administration could dramatically increase accessibility and convenience, helping to overcome common barriers to vaccination like time, travel, and needle phobia.

The convergence of advanced vaccine science with more flexible, consumer-friendly distribution models could represent a powerful new strategy in the long-standing battle against influenza. As DIFF-flu begins its journey through clinical trials, public health officials and competitors worldwide will be watching closely to see if this innovative spray can deliver on its promise to provide safer, broader protection against a persistent global threat.